Bright Minds Bioscience: A Deep Dive

Today we are diving into a firm focused on mental health, whom is also a recently Nasdaq-listed Psychedelic Stock, Bright Minds Biosciences (NASDAQ: DRUG). The firm is focused on the development of second generation psychedelic pharmaceuticals for treatment of neuropsychiatric disorders, which will maintain IP protections, unlike its peers whom are largely focused on first generation psychedelic compounds.

As of the last quarter, the company had $22M cash on the balance sheet with only 12M shares outstanding. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs, with members of its scientific team including renowned scientists like Dr. Alan Kozikowski and Dr. Gideon Shapiro.


FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

Giant Mining Encounters Native Copper As Hole MHB-34 Hits 563 Metres Depth

Verses Hits Commercialization Stage With Genius AI Platform

Related News

Bright Minds Expands Leadership, Scientific Advisory Teams

Bright Minds Biosciences (CSE: DRUG) this morning enhanced its leadership team. The company appointed two...

Tuesday, April 27, 2021, 08:44:04 AM

Bright Minds Begins Phase 1 Clinical Trials Focused On Treating Dravet Syndrome

Phase 1 trials are officially underway for Bright Minds Biosciences (CSE: DRUG) and their lead...

Wednesday, August 31, 2022, 08:52:31 AM

Bright Minds Bioscience Approved For Nasdaq Listing

There’s another Canadian firm set to trade on the Nasdaq market. Bright Minds Bioscience (CSE:...

Wednesday, November 3, 2021, 08:50:22 AM

Bright Minds Applies For Nasdaq Listing

Bright Minds Biosciences (CSE: DRUG) has an eye for the US big boards. The company...

Wednesday, June 16, 2021, 07:33:59 AM

Bright Minds Biosciences: Corporate Overview

Bright Minds Biosciences Inc. (CSE: DRUG) is a small-cap preclinical biosciences company that is attempting to...

Monday, May 31, 2021, 02:43:00 PM